QuantiChrom™ Hemoglobin Assay KitQuantiChrom™ Hemoglobin Assay Kit
Move your mouse over image or click to enlarge

QuantiChrom™ Hemoglobin Assay Kit

For quantitative determination of hemoglobin and evaluation of drug effects on hemoglobin metabolism.

• Sensitive and accurate. Linear detection range 0.9 - 200 mg /dL hemoglobin in 96-well plate assay.

• Simple and high-throughput. The "mix-and-read" procedure involves addition of a single working reagent and reading the optical density. Can be readily automated as a high-throughput assay in 96-well plates for thousands of samples per day.

• Safety. Reagents are non-toxic.

• Versatility. Assays can be executed in 96-well plate or cuvet.

HEMOGLOBIN (Hb) is made of four globin chains each carrying a heme group. It is carried by red blood cells and transports oxygen from the lungs to the peripheral tissues to maintain the viability of cells. Quantitation of blood hemoglobin has been a key diagnostic parameter for various diseases such as anemia, polycythemia and dehydration. Simple, direct and automation-ready procedures for measuring hemoglobin concentration are becoming popular in Research and Drug Discovery. BioAssay Systems’ QuantiChrom™ hemoglobin assay kit is based on an improved Triton/NaOH method, in which the hemoglobin is converted into a uniform colored end product. The intensity of color, measured at 400 nm, is directly proportional to hemoglobin concentration in the sample. The optimized formulation exhibits high sensitivity and is ideal for measuring hemolysis in low hemoglobin samples (e.g. serum and plasma).

Cat# Size Price Qty Buy
DIHB-250 250 Tests £262.65

Additional Information

Property Value or Rating
Product Size 250 Tests
Manufacturer BioAssay Systems
Applications For quantitative determination of hemoglobin and evaluation of drug effects on hemoglobin metabolism.
Method OD400nm
Samples Blood, serum, plasma, urine etc
Species All
Detection Limit 0.9 mg/dL
Storage 4°C
Shelf Life 12 months
References Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

2. Liu D et al (2010). Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol. 12(10):993-8. Assay: Hemoglobin in Mouse tissue (Pubmed).

3. Burne-Taney MJ et al (2006). Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol. 176(11):7015-20. Assay: Hemoglobin in Mouse spleen cell (Pubmed).

4. Kasiappan R et al (2009). Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res. 7(4):536-48. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

5. Liu W,et al (2009). Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40(7):2526-31. Assay: Hemoglobin in Rat tissue (Pubmed).

6. Weis SM et al (2008). Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 181(1):43-50. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

7. He Y et al (2009). Effects of cerebral ischemia on neuronal hemoglobin. J Cereb Blood Flow Metab. 29(3):596-605. Assay: Hemoglobin in Rat brain tissue (Pubmed).

8. Frid?n M et al (2010). Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab. 30(1):150-61. Assay: Hemoglobin in Rat brain tissue (Pubmed).

9. Meyer C et al (2010). Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. J Am Coll Cardiol. 55(5):454-9. Assay: Hemoglobin in Human plasma (Pubmed).

10. Singleton PA et al (2010). Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2(1):5. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

11. French CJ et al (2010). Vascular rhexis: loss of integrity of coronary vasculature in mice subjected to myocardial infarction. Exp Biol Med (Maywood) 235(8):966-73. Assay: Hemoglobin in Mouse tissue (Pubmed).

" title="

1. Thaker PH et al (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12(8):939-44. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

2. Liu D et al (2010). Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol. 12(10):993-8. Assay: Hemoglobin in Mouse tissue (Pubmed).

3. Burne-Taney MJ et al (2006). Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol. 176(11):7015-20. Assay: Hemoglobin in Mouse spleen cell (Pubmed).

4. Kasiappan R et al (2009). Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res. 7(4):536-48. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

5. Liu W,et al (2009). Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40(7):2526-31. Assay: Hemoglobin in Rat tissue (Pubmed).

6. Weis SM et al (2008). Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 181(1):43-50. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

7. He Y et al (2009). Effects of cerebral ischemia on neuronal hemoglobin. J Cereb Blood Flow Metab. 29(3):596-605. Assay: Hemoglobin in Rat brain tissue (Pubmed).

8. Frid?n M et al (2010). Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab. 30(1):150-61. Assay: Hemoglobin in Rat brain tissue (Pubmed).

9. Meyer C et al (2010). Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. J Am Coll Cardiol. 55(5):454-9. Assay: Hemoglobin in Human plasma (Pubmed).

10. Singleton PA et al (2010). Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2(1):5. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

11. French CJ et al (2010). Vascular rhexis: loss of integrity of coronary vasculature in mice subjected to myocardial infarction. Exp Biol Med (Maywood) 235(8):966-73. Assay: Hemoglobin in Mouse tissue (Pubmed).

" target="_blank">

1. Thaker PH et al (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12(8):939-44. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

2. Liu D et al (2010). Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol. 12(10):993-8. Assay: Hemoglobin in Mouse tissue (Pubmed).

3. Burne-Taney MJ et al (2006). Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol. 176(11):7015-20. Assay: Hemoglobin in Mouse spleen cell (Pubmed).

4. Kasiappan R et al (2009). Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. Mol Cancer Res. 7(4):536-48. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

5. Liu W,et al (2009). Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40(7):2526-31. Assay: Hemoglobin in Rat tissue (Pubmed).

6. Weis SM et al (2008). Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 181(1):43-50. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

7. He Y et al (2009). Effects of cerebral ischemia on neuronal hemoglobin. J Cereb Blood Flow Metab. 29(3):596-605. Assay: Hemoglobin in Rat brain tissue (Pubmed).

8. Frid?n M et al (2010). Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab. 30(1):150-61. Assay: Hemoglobin in Rat brain tissue (Pubmed).

9. Meyer C et al (2010). Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. J Am Coll Cardiol. 55(5):454-9. Assay: Hemoglobin in Human plasma (Pubmed).

10. Singleton PA et al (2010). Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2(1):5. Assay: Hemoglobin in Mouse tumor tissue (Pubmed).

11. French CJ et al (2010). Vascular rhexis: loss of integrity of coronary vasculature in mice subjected to myocardial infarction. Exp Biol Med (Maywood) 235(8):966-73. Assay: Hemoglobin in Mouse tissue (Pubmed).

Related Documents